THE PRIORITIZE STUDY: A Pragmatic, Randomized Study of Oral Regimens for Hepatitis C: Transforming Decision-Making for Patients, Providers, and Stakeholders
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 20 Jun 2018
At a glance
- Drugs Dasabuvir (Primary) ; Elbasvir/grazoprevir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms PRIORITIZE
- 21 Mar 2018 Planned number of patients changed from 2670 to 1670.
- 21 Mar 2018 Planned End Date changed from 1 Feb 2021 to 1 Feb 2022.
- 21 Mar 2018 Planned primary completion date changed from 1 Aug 2020 to 1 Jan 2019.